Corcept Therapeutics Incorporated (CORT)
| Market Cap | 3.66B |
| Revenue (ttm) | 741.17M |
| Net Income (ttm) | 104.66M |
| Shares Out | 105.19M |
| EPS (ttm) | 0.87 |
| PE Ratio | 39.84 |
| Forward PE | 41.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,305,349 |
| Open | 38.89 |
| Previous Close | 70.20 |
| Day's Range | 32.99 - 39.00 |
| 52-Week Range | 32.99 - 117.33 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 130.20 (+274.14%) |
| Earnings Date | Nov 4, 2025 |
About CORT
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t... [Read more]
Financial Performance
In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $130.2, which is an increase of 274.14% from the latest price.
News
Why Corcept Therapeutics stock crashed today and what comes next?
Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing's syndrome. The se...
Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug
The FDA cited insufficient evidence of effectiveness for relacorilant in patients with Cushing syndrome and hypertension, sending the stock sharply lower.
US FDA declines to approve Corcept's drug for rare hormonal disorder
The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' hormone-blocking drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
Are There Red Flags in the Trial Results?
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated ( CORT) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean M...
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 202...
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Transition To New Specialty Pharmacy Well Underway
Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to it...
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics
ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to ther...
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Corcept Primed For An Upside EPS Surprise
My September quarter EPS forecast of $0.29 for Corcept could meaningfully beat analyst projections of $0.17. Approval of the company's Relacorilant medication by the FDA will essentially resolve any g...
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early
Corcept's Q2 2025 results were impacted by specialty pharmacy bottlenecks and discounting, masking robust underlying 60% growth in demand for its therapies. Revenue guidance was trimmed on fulfillment...
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secret...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025....
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Applications of Relacorilant and Corcept's other cortisol modulators are not being valued by investors. Results from the Rosella clinical trials showcase the multifaceted applications of cortisol modu...
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
Corcept Therapeutics remains a strong buy, with recent stock weakness attributed to put options trading rather than fundamental issues. Management maintains aggressive 2025 and long-term revenue guida...